Anteris Technologies Receives Full Regulatory Clearance From The French National Agency For Medicines And Health Products Safety For The DurAVR Transcatheter Heart Valve Global Pivotal Trial In Patients With Severe Calcific Aortic Stenosis

Loading news article.

Anteris Technologies Receives Full Regulatory Clearance From The French National Agency For Medicines And Health Products Safety For The DurAVR Transcatheter Heart Valve Global Pivotal Trial In Patients With Severe Calcific Aortic Stenosis | WAPE

Anteris Technologies Receives Full Regulatory Clearance From The French National Agency For Medicines And Health Products Safety For The DurAVR Transcatheter Heart Valve Global Pivotal Trial In Patients With Severe Calcific Aortic Stenosis

Article summary

Related companies

Comments —